• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人尿激酶原酶及活性形式的生物学和溶栓特性——II. 兔和松鼠猴体内天然及重组尿激酶的代谢

Biological and thrombolytic properties of proenzyme and active forms of human urokinase--II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys.

作者信息

Collen D, De Cock F, Lijnen H R

出版信息

Thromb Haemost. 1984 Aug 31;52(1):24-6.

PMID:6495260
Abstract

The turnover of recombinant pro-urokinase (Rec-pro-UK), recombinant urokinase (Rec-UK) and natural urinary urokinase (Nat-UK) was studied in rabbits and in squirrel monkeys (Saimiri sciureus). Following intravenous injection, urokinase activity disappeared rapidly from the blood. The initial disappearance rate could be described by a single exponential term with a t 1/2 of 3 to 6 min for each molecular form of urokinase in both species. Urokinase related antigen, measured with a radioimmunoassay in the plasma of the squirrel monkeys disappeared with a t 1/2 of 3.5 min for Rec-pro-UK, 6.0 min for Rec-UK and 8.0 min for Nat-UK. The clearance and organ distribution of Rec-pro-UK, Rec-UK and Nat-UK was studied with the use of 125I-labeled preparations. In each case the radioactivity initially disappeared rapidly from the plasma, also with a t 1/2 of a few min, but then the disappearance rate slowed down. Labeled Rec-UK in which the active site histidine was irreversibly blocked by alkylation, disappeared equally rapidly from the plasma. Measurement of the organ distribution of 125I at different time intervals revealed that all three types of urokinase were rapidly accumulated in the liver, which was followed by release of degradation products in the blood. Experimental hepatectomy prolonged the t 1/2 of each type of urokinase very markedly (t 1/2 greater than 30 min). These findings indicate that urokinase is rapidly removed from the blood by clearance and degradation in the liver. Recognition by the liver does not require a functional active site and is not mediated via carbohydrate side chains. Inactivation by plasma protease inhibitors does not represent a significant pathway of urokinase inhibition in vivo.

摘要

在兔和松鼠猴(松鼠猴属)中研究了重组人尿激酶原(Rec-pro-UK)、重组尿激酶(Rec-UK)和天然人尿激酶(Nat-UK)的代谢情况。静脉注射后,尿激酶活性迅速从血液中消失。两种动物中每种尿激酶分子形式的初始消失速率可用单一指数项描述,半衰期为3至6分钟。用放射免疫分析法测定松鼠猴血浆中的尿激酶相关抗原,Rec-pro-UK的半衰期为3.5分钟,Rec-UK为6.0分钟,Nat-UK为8.0分钟。使用125I标记的制剂研究了Rec-pro-UK、Rec-UK和Nat-UK的清除率及器官分布。在每种情况下,放射性最初也迅速从血浆中消失,半衰期为几分钟,但随后消失速率减慢。活性位点组氨酸被烷基化不可逆阻断的标记Rec-UK从血浆中消失速度同样很快。在不同时间间隔测量125I的器官分布表明,所有三种类型的尿激酶都迅速在肝脏中蓄积,随后血液中出现降解产物。实验性肝切除非常显著地延长了每种尿激酶的半衰期(半衰期大于30分钟)。这些发现表明,尿激酶通过肝脏中的清除和降解迅速从血液中清除。肝脏的识别不需要功能性活性位点,也不是通过碳水化合物侧链介导的。血浆蛋白酶抑制剂的失活在体内并非尿激酶抑制的重要途径。

相似文献

1
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys.人尿激酶原酶及活性形式的生物学和溶栓特性——II. 兔和松鼠猴体内天然及重组尿激酶的代谢
Thromb Haemost. 1984 Aug 31;52(1):24-6.
2
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.人尿激酶原酶及其活性形式的生物学和溶栓特性——III. 天然和重组尿激酶在实验性颈静脉血栓形成兔中的溶栓特性
Thromb Haemost. 1984 Aug 31;52(1):27-30.
3
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.人尿激酶原酶及活性形式的生物学和溶栓特性——IV. 几种哺乳动物血浆纤溶反应的变异性
Thromb Haemost. 1984 Aug 31;52(1):31-3.
4
Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.人外源性(组织型)纤溶酶原激活剂在兔体内的周转率。
Thromb Haemost. 1981 Oct;46(3):658-61.
5
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.人尿激酶原酶及其活性形式的生物学和溶栓特性——I. 从人尿中获得或通过重组DNA技术制备的尿激酶在人血浆中的体外纤溶和纤维蛋白原溶解特性
Thromb Haemost. 1984 Aug 31;52(1):19-23.
6
Pharmacokinetics of single chain forms of urokinase-type plasminogen activator.单链尿激酶型纤溶酶原激活剂的药代动力学
J Pharmacol Exp Ther. 1987 Jul;242(1):245-50.
7
Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase.
Thromb Haemost. 1979 Oct 31;42(3):885-94.
8
The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.低密度脂蛋白受体相关蛋白(LRP)在大鼠体内重组单链尿激酶型纤溶酶原激活剂的血浆清除及肝脏摄取中的作用
Thromb Haemost. 1997 Apr;77(4):710-7.
9
Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.尿激酶原(pro-urokinase)的酶原前体形式实现有效且纤维蛋白特异性的血栓溶解。一项体外及在两种动物物种中的研究。
J Clin Invest. 1984 Jun;73(6):1731-9. doi: 10.1172/JCI111381.
10
Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin.纤维蛋白存在下高分子量和低分子量尿激酶活性的比较研究
Thromb Haemost. 1982 Feb 26;47(1):36-40.

引用本文的文献

1
Platelet-targeted thrombolysis for treatment of acute ischemic stroke.血小板靶向溶栓治疗急性缺血性脑卒中。
Blood Adv. 2023 Feb 28;7(4):561-574. doi: 10.1182/bloodadvances.2021006691.
2
Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction.
J Thromb Thrombolysis. 1996;3(4):385-390. doi: 10.1007/BF00133082.
3
Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.
J Gastroenterol. 1994 Dec;29(6):745-50. doi: 10.1007/BF02349281.
4
Novel thrombolytic agents.新型溶栓剂。
Cardiovasc Drugs Ther. 1994 Dec;8(6):801-11. doi: 10.1007/BF00877398.
5
The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.低密度脂蛋白受体相关蛋白介导组织因子途径抑制剂的细胞降解。
Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6664-8. doi: 10.1073/pnas.91.14.6664.
6
New strategies in the development of thrombolytic agents.溶栓药物开发的新策略。
Blut. 1988 Oct;57(4):147-62. doi: 10.1007/BF00319543.